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The mood disorder prodrome is conceptualized as a symptomatic, but not yet clinically diag-
nosable stage of an affective disorder. Although a growing area, more focused research
is needed in the pediatric population to better characterize psychopathological symptoms
and biological markers that can reliably identify this very early stage in the evolution of
mood disorder pathology. Such information will facilitate early prevention and intervention,
which has the potential to affect a person’s disease course.This review focuses on the pro-
dromal characteristics, risk factors, and neurobiological mechanisms of mood disorders.
In particular, we consider the influence of early-life stress, inflammation, and allostatic
load in mediating neural mechanisms of neuroprogression. These inherently modifiable
factors have known neuroadaptive and neurodegenerative implications, and consequently
may provide useful biomarker targets. Identification of these factors early in the course
of the disease will accordingly allow for the introduction of early interventions which aug-
ment an individual’s capacity for psychological resilience through maintenance of synaptic
integrity and cellular resilience. A targeted and complementary approach to boosting both
psychological and physiological resilience simultaneously during the prodromal stage of
mood disorder pathology has the greatest promise for optimizing the neurodevelopmental
potential of those individuals at risk of disabling mood disorders.
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INTRODUCTION
There is increasing appreciation for the need to both identify and
treat mood disorders during their earliest stages (1). Although
some dispute remains, maladaptive changes in mood and behavior
first become evident during the prodromal period (2). However,
the low specificity of these changes makes the prodromal stage
difficult to definitively characterize prior to disease onset (3).
Observable changes in mood and general physiologic function-
ing can include increases in sadness, anhedonia, irritability, anger,
and anxiety, together with alterations in sleep and energy (4).
Correlating these symptoms with prodromal biomarkers offers an
exciting juncture whereby targeted interventions could be oppor-
tunistically employed to prevent neurodegenerative changes from
accruing as the disease progresses (5). The potential to inter-
vene during the prodromal stage of psychiatric illness through the
detection and remediation of novel biomarkers has perhaps been
best studied in schizophrenia, wherein most individuals experi-
ence a lengthy prodromal period prior to the full emergence of
diagnosable psychotic symptoms (6). As an exemplar, low levels
of nervonic acid appear to be a risk factor for conversion from
high-risk to frank psychosis (7), and this risk of conversion may
be reduced by targeted omega-3 fatty acid supplementation (8).
Encouraging results from this work have renewed interest in the
early detection of affective disorders, particularly bipolar disorder,
with the hope that earlier and more targeted interventions might
slow disease progression (3, 9–12). This can significantly impact
neuroprogression and subsequent disease course for the individual
(13). This concept of “neuroprogression” refers to the cumulative
restructuring of the central nervous system which in turn medi-
ates the development and persistence of psychiatric illness (14, 15).
This process results from disturbances in inflammatory mediators,
neurotrophins, oxidative stress, and energy regulation (14, 15).
BIOMARKER STRATEGIES FOR PRODROMAL MOOD
DISORDERS
STRESS AND ALLOSTATIC LOAD
Stress sensitization and early detection
Stress is one of the best-studied mediators by which genetic vul-
nerabilities are translated into mood disorder pathology through
the process of neuroprogression (16–18). Numerous studies have
www.frontiersin.org April 2014 | Volume 5 | Article 34 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Walker et al. Early stage affective disorders
demonstrated that both depression and bipolar disorder are more
prevalent in individuals who have experienced adverse early-life
events. This is partly because such experiences prime future phys-
iologic and neural responses to stress, elicit a state of chronic
inflammation (19), alter cellular mediators of plasticity and energy
metabolism, and increase cellular “wear and tear” (20–22). Early-
life stress (2) can be particularly deleterious because of its poten-
tial to influence the programing of the hypothalamic–pituitary–
adrenal (HPA) axis (23) to induce persistent sensitization of
neuroendocrine, autonomic, oxidative, and immune responses to
stress. Over time these sensitized systems cumulatively contribute
to the cellular and synaptic alterations underlying neuroprogres-
sion (21, 24–26). Specific examples include changes in reactivity
of inflammatory cytokines [e.g., interleukin 6 (IL-6)] (25), alter-
ations in markers for lipid peroxidation [e.g., 8-iso-prostaglandin
F (2α)],oxidative damage to DNA (8-hydroxy-2′-deoxyguanosine)
and RNA (8-hydroxyguanosine) (24), as well as altered cortisol,
adrenocorticotropic hormone, and corticotrophin releasing fac-
tor responses (26). Identification of the state of physiologic and
cellular resilience or sensitivity to stress may provide an important
indicator of the level of neuroprogression and stress-mediated dis-
ease pathology for affective disorders,potentially prior to the initial
manifestation of the mood episode (22).
One mechanism whereby HPA axis sensitization is likely to
occur is through epigenetic regulation of stress response processes
(21, 27). Evidence shows that exposure to various forms of stress
result in multiple epigenetic changes in limbic regions as well as
the HPA axis (21, 27). Interestingly, a recent study by Klendel
and colleagues (18) found that only individuals who exhibited
allele-specific DNA demethylation in functional glucocorticoid
response elements of FK506 binding protein 5 (FKBP5), were
prone to developing persistent cortisol dysregulation (18, 21).
Further, this association was found to be dependent on an inter-
action effect with trauma in early life, suggesting that key devel-
opmental stages are directly related to stability of the observed
effects across time (18). In another study, significant interactions
between peripheral FKBP5 mRNA expression and disease progres-
sion were reported, suggesting that polymorphisms in the gene
directly impact the extent of neuroendocrine dysregulation, and
corresponding neuroprogression (28). The FKBP5 risk allele and
corresponding levels of mRNA expression may represent useful
biomarkers. These markers could be employed to identify individ-
uals in the prodromal stages of stress-sensitive psychiatric disor-
ders, such as major depression or bipolar disorder. Such detection
would facilitate early intervention and could improve resilience
and alleviate allostatic load in the prodromal individual.
Early-life stress and accumulation of allostatic load
Accumulation of allostatic load is a key mechanism through which
early-life stress is thought to result in psychopathology (29). This
is mediated via a series of enduring adaptive changes across a range
of systems primed both to respond rapidly to challenge, as well as
to restore homeostatic equilibrium (30). Adaptive allostatic mech-
anisms may fail when chronically challenged or when regulatory
systems falter. This leads to a state of allostatic overload, which
is thought to considerably impact the clinical course of mood
disorders (31–33). Without sufficient opportunity for recovery,
the brain and body are repeatedly exposed to molecular media-
tors of stress that can increase the level of cellular “wear and tear”
(33). These mediators, which include metabolic factors, inflamma-
tory cytokines, neurotrophins, and oxidative species, collectively
impact an individual’s mental and physical resilience as outlined
below [for more detailed reviews see Ref. (6, 34, 35)]. Both phys-
iological (i.e., immune and/or metabolic) and psychological (i.e.,
bullying) stressors contribute significantly to allostatic load, and
thus need to be considered together when assessing both risk and
relative staging of mood disorder pathology (6, 34).
Enhancing an individual’s capacity to buffer the physiologic
toll that accumulates through allostatic overload should be con-
sidered an important early intervention strategy. As allostatic load
accumulates and attempts to maintain cellular homeostasis fail,
cell danger signals are propagated and pro-apoptotic cell signaling
pathways become increasingly engaged (36–39). This may play a
role in medical comorbidities such as heart disease (40), as well
as interfere with the therapeutic mechanisms of antidepressants
and mood stabilizers to impair treatment efficacy (41–43). Inter-
nal stressors that activate the HPA axis and associated allostatic
systems can limit an individual’s capacity for allostasis even prior
to the onset of external stressors (36). For example, an endogenous
load can build through the expression of homocysteine or inflam-
matory cytokines, limiting the capacity of adaptive responses in the
face of subsequent stressors. Interventions that counter this load
and reduce levels of proinflammatory mediators or interfere with
their neuromodulatory actions could limit neuroprogression in
both bipolar and unipolar depression, as well as enhance capacity
for antidepressant efficacy (44–46).
INFLAMMATORY PROFILE
Stress during earlier life is not only associated with disruption of
the HPA axis, but may also serve to sensitize proinflammatory
responses to future insults (47–49). Inflammatory mechanisms
are increasingly appreciated for their critical role in mood disor-
der pathophysiology, in particular via their regulation of neuronal
excitability, synaptic transmission, synaptic plasticity and neu-
ronal survival (41, 50, 51). Of specific interest are proinflammatory
mediators, such as cytokines [i.e., interleukin 1, IL-6, and tumor
necrosis factor alpha (TNF-α)] and C-reactive protein (CRP). CRP
is often used as a biomarker for inflammation in studies due to
its relationship with proinflammatory cytokines and role in the
immune response. As demonstrated by Slopen and colleagues (49),
individuals at ages 10 and 15 who reported adverse life events at
critical stages between the ages of 1.5 and 8 years were found to
have significantly increased levels of CRP and IL-6. These height-
ened concentrations were correlated with immune activation and
depressive-like symptoms. Notably, increased CRP levels have been
used previously to predict depression severity and recurrence rates
in males (48, 52).
There is a growing literature supporting the use of inflam-
matory biomarkers as predictors of ensuing mood disorder
pathology (22). Research to date has been focused on inves-
tigating the relationship between inflammatory cytokines and
affective disorders in adults; however, their specific role in early
onset/adolescent psychopathology is less well explored (53).
Cytokines are thought to influence neurodevelopment during key
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stages, such as adolescence, interacting with biological systems
including those of stress hormones and gonadal hormones (53).
As such, perturbation of inflammatory balance in adolescents may
significantly contribute to neuroprogression and development of
psychiatric illness (19, 53, 54). For example, elevated serum lev-
els of TNF-α, IL-6, and interleukin-10 (IL-10) have been reported
during the early stages of bipolar disorder (55), and CRP appears
to be a biomarker of de novo depression risk (56).
As the mood disorder pathology progresses, an increasing num-
ber of proinflammatory cytokines are observed, including elevated
levels of interferon gamma (IFN-γ) (22, 54, 55). Notably, increases
in IFN-γ are associated with dysregulation of the tryptophan
metabolite pathway via direct role in indoleamine 2,3-dioxygenase
(IDO) activation. Activation of IDO is commonly found in later
stages of mood disorders, and is a biomarker of depression-like
behavior mediated by neural inflammation in animal models
(48). Proinflammatory cytokines activate IDO, resulting in deple-
tion of serotonin and augmentation of quinolinic acid (QUIN)
metabolism over kynurenic acid (KYNA). Tryptophan metabo-
lites (kynurenine, KYNA, 3-hydroxykynurenine, and QUIN) act
as neuromodulators to influence behavioral, neuroendocrine, and
neurochemical aspects of depression (57–60). Consequently, this
accumulation of QUIN facilitates neurodegeneration over neu-
roprotection, impacting mood disorder neuroprogression and
resultant disability (61).
It is noteworthy to mention several other findings regard-
ing altered inflammation in youth with psychiatric pathology.
Increased mRNA and protein expression levels of IL-1β, IL-6, and
TNF-α were reported in the anterior prefrontal cortex of adoles-
cent suicide victims compared with normal control subjects (62).
Elevated levels of inflammatory cytokines (among others: TNF-α,
IL-1β, IL-6, and IFN-γ) were also observed in the serum of pedi-
atric patients who experienced first-episode psychosis, in addition
to increased leukocyte counts and evidence of blood–brain barrier
damage (63). Quantification of inflammatory biomarkers (e.g.,
TNF-α, IL-6, IL-10, or CRP) may thus prove useful for detecting
individuals at risk for developing a mood disorder. A recent study
by Byrne and colleagues (64) suggests that levels of peripheral
cytokines (e.g., IFN-γ) and CRP in salivary samples may correlate
with serum samples in young people. Salivary assay may prove to
be a simpler, less invasive method of estimating peripheral lev-
els of inflammatory markers in adolescents (64). This provides
one avenue whereby prodromal individuals could potentially be
identified and their disease onset delayed.
DIMINISHED SYNAPTIC INTEGRITY
Homeostatic control of synaptic connections within key mood-
related circuits plays a critical role in the etiology of mood dis-
orders (65). Stress and inflammation as discussed in previous
sections are implicated in disruption of synaptic signaling and
integrity during the early stages of mood disorder pathogenesis.
This is mediated in part through the inhibition of neurotrophin
function, of which brain derived neurotrophic factor (BDNF) is
the most thoroughly characterized. BDNF plays an important
role in neuronal development, survival, and function, including
activity-dependent synaptic plasticity (66). Synaptic plasticity is
characterized by various processes, including synaptic remodeling,
synaptogenesis, long-term potentiation, and long-term depres-
sion, all of which critically mediate the flow of electrochemical
information throughout the central nervous system (67, 68).
Stress, allostatic load, inflammation, antidepressants, and mood
stabilizers exert major effects on signaling pathways that regu-
late cellular plasticity, suggesting these are critical neurobiologi-
cal mediators of mood dysfunction and therapeutic intervention
(69–72).
Glycogen synthase kinase-3 (GSK-3), part of the signaling cas-
cade regulated by BDNF, plays an important role in synaptic home-
ostasis through regulation of synaptic deconsolidation (pruning)
and glutamate receptor cycling (73). Increased GSK-3-mediated
synaptic deconsolidation has been suggested to be an important
factor contributing to reduced spine density in mood disorders
(74). Additionally, levels of activated GSK-3 are increased in post-
mortem brain tissue from individuals with unipolar and bipolar
depression (74). In addition to BDNF, GSK-3 is deactivated by sig-
nals originating from numerous signaling pathways demonstrated
to be dysregulated in mood disorders (e.g., Wnt and PI3K path-
ways), and is either the direct or downstream target of many mood
stabilizer and antidepressant medications (75). GSK-3 activity is
modulated by serotonin and dopamine, and is a critical node at
the intersection of multiple neurotransmitter and cell signaling
cascades (68). As a result, GSK-3 modulates not only synaptic plas-
ticity but also apoptotic mechanisms and, in turn, plays a critical
role in mediating cellular resilience (75). For this reason, GSK-3
has received much attention for its potential to be targeted as an
early intervention strategy during the prodrome period.
IDENTIFYING IMPAIRED CELLULAR RESILIENCE
Stress, allostatic overload, and neuroinflammation function
together to impair synaptic plasticity and cellular resilience. Dis-
rupted plasticity along with increased cellular vulnerability con-
tributes significantly to the pathophysiology of mood disorders
and directly to the neuroprogressive nature of the disease course (3,
76). Some of the key mechanisms of disease progression affecting
cellular resilience include: oxidative stress, decreased neurotrophic
factor expression, reduced neurogenesis, impaired regulation of
calcium, altered endoplasmic reticulum and mitochondrial func-
tion, together with dysregulated energy metabolism and insulin
signaling. Each of these mechanisms are mediated by allostatic
overload and neuroinflammation [for detailed reviews see Ref. (3,
36, 76–78)]. Together, these processes demonstrate that in addition
to synaptic integrity, maintenance of cellular homeostasis is critical
for facilitating cellular resilience and attenuating mood disorder
pathogenesis (79), which is also likely to enhance the capacity for
treatment response during later stages of the disorder (80).
Cellular vulnerability and resilience are mediated by apop-
totic and anti-apoptotic intracellular signaling cascades, respec-
tively. Apoptosis is important for the regulation of develop-
mental processes and prevention of cancerous growths. Exces-
sive apoptosis in neuronal systems, however, leads to neurode-
generation and certain cell populations are at increased risk
of stress-mediated apoptotic cell death (80). Apoptosis is a
tightly regulated and energy-dependent process, which coordi-
nates programed cell death in response to different stimuli (81).
This can occur through stimulation of death receptor proteins
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[i.e., tumor necrosis factor (TNF) receptor] by cytokines of the
TNF superfamily or in response to mitochondrial degradation.
These stimuli result in activation of executioner caspases that
function to coordinate cellular process necessary for apoptosis,
including cessation of cell repair processes and cell cycle pro-
gression, cytoskeletal and nuclear disassembly, and flagging the
cell for phagocytosis (82). Distinct classes of antidepressants
and mood stabilizers have been demonstrated to facilitate cellu-
lar resilience to prevent progression of pro-apoptotic processes,
and novel treatments are currently being developed to target
these specific mechanisms (83). Biomarkers that characterize the
level of neuronal vulnerability relative to resilience may prove
useful as biomarkers of prodromal mood disorder pathology.
This has been demonstrated for later stages of bipolar disorder
(84), however more studies are needed to determine the util-
ity of such cell danger biomarkers during the mood disorder
prodrome (22).
OPPORTUNITIES FOR PREVENTION AND INTERVENTION
IDENTIFYING VULNERABILITIES AND BUILDING RESILIENCE AT THE
CELLULAR LEVEL
Identification of individuals at risk of developing a mood disorder,
or those in the prodromal stage, provides a potential opportunity
to target these mechanisms for neuroprotective interventions that
enhance cellular resilience, maintain synaptic plasticity and boost
psychological resilience (Figure 1) (85). One of the longest held
notions of brain plasticity is that certain critical periods or win-
dows exist in development, during which circuitry is consolidated
for lifetime functionality. Recently, there is a rising consensus that
developmentally induced plasticity can, to an extent, be reversed
by “re-opening” those windows of plasticity (86). Hyman and
Nestler (87) have underscored the importance of shifting the brain
into an “adaptive state” to necessitate the antidepressant response.
Their theory of “initiation and adaption” is exemplified by psy-
chotropic drugs wherein primary molecular targets that initiate
alterations in brain function activate homeostatic mechanisms
that return the system to an adaptive and treatment responsive
state (87). Plasticity and cellular resilience are thus necessary for
the efficacy of antidepressants and mood stabilizing treatments.
McGorry and colleagues (6, 88) and others (89) have demon-
strated this concept with pre-psychotic interventions, and repeat-
edly emphasized the need to take advantage of the “windows of
opportunity” present within the prodromal stages of psychiatric
disease (6, 88, 89). During this stage, the course of the disease
remains theoretically plastic and amenable to intervention (90).
Previous literature indicates that once risk or prodromal symp-
toms of mood disorders are identified, there is some (91), but not
unequivocal (92) evidence that early intervention in adolescents
can significantly reduce mood-related symptoms and incidence
of fully diagnosable psychiatric disorders such as depression (93–
95). Neuroprotective pharmacotherapies together with appropri-
ate psychotherapy may reduce the risk of neuropsychiatric disease
progression in young people which, together with allostatic load
reducing behavioral interventions, may significantly slow the tra-
jectory of the disease course into adulthood (6, 36, 96). Such
interventions may include reducing lifestyle mediators of allostatic
load (19, 97).
FIGURE 1 | A representation of the conceptual balance between
vulnerability and resilience in prodromal individuals. The scale’s balance
beam teeters between vulnerability and resilience as scale pans are loaded
with different positive and negative biological, psychological and social
factors. The presence or absence of these factors influence the ability of
the individual to cope with stressors, and maintain allostasis. (A) Prodromal
individuals are somewhat predisposed to vulnerability; but with intervention
(B) an individual may adopt more adaptive environmental coping strategies,
support mechanisms, general healthy lifestyle choices, and/or receive
pharmacological interventions that collectively enhance physiological and
psychological resilience.
COGNITIVE AND BEHAVIORAL INTERVENTIONS TO BUFFER STRESS
AND BUILD RESILIENCE
Individuals provided with effective social and emotional sup-
port to help cope with stressors that are adverse and potentially
taxing will be much better placed to limit associated biological
costs and maintain allostasis (98). The absence of emotional or
social support and the implementation of maladaptive coping
strategies can enhance the toxic effects of stress and contribute
to allostatic overload (98). Exposure to regular and controllable
stressors over the course of childhood and adolescence is essen-
tial for the development of effective coping strategies. Through
such exposure, an individual can develop a repertoire of these
coping strategies. Mathew and Nanoo (99) found that adaptive
coping strategies (e.g., employing self-control, accepting respon-
sibilities, problem solving, seeking social support, or positive re-
appraisal) are protective for suicide risk in adolescents. Conversely,
maladaptive coping strategies, such as confrontation, distancing,
and escape-avoidance were reported to be significant risk factors
associated with adolescent suicide attempts (99). These findings
provide evidence to support the notion that coping strategies
can act as protective factors against both the development and
progression of mood disorders. Importantly, educating children
and adolescents in protective coping skills may be a promising
intervention that could be implemented as early as elementary
school. In recent years, patterns of threat perception such as opti-
mism have attracted much attention in relation to later mood,
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coping, and immune change in response to stress (100, 101). More-
over, it has been found to be protective against the development
of depressive symptoms in later life (102). Its potential role in
buffering against the negative emotional consequence of adverse
events has led to a view of optimism as an index of resilience
(103). Optimists may also choose lifestyles that promote phys-
ical as well as mental health, thereby reducing other aspects of
allostatic load.
Healthy lifestyle, similar to optimism, provides a solid founda-
tion for adaptation, and increases available resources for buffering
the neurodegenerative effects of stress. Specifically, previous lit-
erature highlights the importance of healthy diet, adequate sleep,
avoidance of smoking, and sufficient exercise (104). A population-
based study reported higher emotional well-being among physi-
cally active youths, independent of social class and health status
(105). Across a 2-year period, Motl and colleagues (106) found
changes in physical activity were inversely related to a change
in depressive symptoms. Levels of physical activity in childhood
can modulate the risk of adult depression (107). Exercise modu-
lates many of the core biomarkers of neuroprogression, including
inflammation, oxidative stress, and neurotrophins (108). Poor
eating habits and sleep have been linked to the manifestation
of toxic stress and unhealthy growth in pediatrics by disrupt-
ing the architecture of the plastic, adaptive brain (109). There is
now extensive evidence that poor diet quality is a risk for ado-
lescent depression (110), and new data suggests that maternal
diet influences the mental health of offspring (111). Similarly,
smoking increases the risk of mood and anxiety disorders, and
appears to influence similar biological pathways (112, 113). Par-
ents and care givers of younger children need to be informed of
the potential impact that a healthy lifestyle can have in mitigat-
ing mood-related symptoms and problematic behaviors. Low-risk
interventions such as those aforementioned are critical for enhanc-
ing both psychological and biological resilience to stress. When
such perspectives and lifestyle health behaviors are consolidated
early in childhood and adolescence, the cumulative effect may be
meaningful (103).
CONCLUSION
Early intervention offers the possibility of altering the trajec-
tory of mood disorder pathology. In so doing, we may curtail
the progressive nature of the illness, both through neuropro-
tection and maintenance of peripheral health. Prevention and
intervention treatments should go beyond stabilizing mood to
include various and complementary strategies for reducing allo-
static load, perhaps through psychoeducation and lifestyle-related
interventions, including effective stress management. The com-
bination of these techniques with specific pharmacotherapies
may significantly improve functional outcomes by both reduc-
ing cellular insults and enhancing resilience. In so doing, this
optimizes the capacity for maintenance of synaptic integrity
and cellular resilience, which must be aggressively targeted as a
therapeutic strategy during the prodromal stage of mood dis-
order pathology (90). This neuroprotective approach not only
slows neuroprogression associated with the disease, but lays
a foundation for more treatment-responsive outcomes during
later stages.
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